34.51 0.00 (0.00%)
After hours: 4:19PM EDT
|Bid||33.51 x 1000|
|Ask||34.94 x 800|
|Day's Range||32.31 - 35.20|
|52 Week Range||17.03 - 37.45|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 5, 2018 - Nov 9, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||36.67|
MARKET PULSE PetIQ Inc. (petq) shares soared 10% in Wednesday premarket trading after the pet health and wellness company reported second-quarter sales that nearly doubled. PetIQ reported sales of $171.
The Eagle, Idaho-based company said it had net income of 16 cents per share. Earnings, adjusted for non-recurring costs, came to 66 cents per share. The results topped Wall Street expectations. The average ...
Second Quarter Net Sales Increase 96% Year-Over-Year to $171.1 Million. Opened 20 Wellness Centers Year-to-Date. Company Raises Net Sales Outlook for Full Year 2018.
NEW YORK, NY / ACCESSWIRE / August 14, 2018 / PetIQ, Inc. Class A (NASDAQ: PETQ ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 14, 2018 at 4:30 PM Eastern Time. ...
EAGLE, Idaho, July 24, 2018-- PetIQ, Inc., a leading pet medication and wellness company, today announced it will report results for the second quarter ended June 30, 2018 on Tuesday, August 14, 2018 after ...
LONDON, UK / ACCESSWIRE / June 19, 2018/ If you want a free Stock Review on ZTS sign up now at www.wallstequities.com/registration. Under evaluation this morning are these four stocks: Flexion Therapeutics Inc. (NASDAQ: FLXN), Momenta Pharmaceuticals Inc. (NASDAQ: MNTA), PetIQ Inc. (NASDAQ: PETQ), and Zoetis Inc. (NYSE: ZTS).
EAGLE, Idaho, June 06, 2018-- PetIQ, Inc., a leading pet medication and wellness company, today announced that management will participate in the Jefferies 2018 Consumer Conference in Nantucket, MA.. The ...
EAGLE, Idaho, May 31, 2018-- PetIQ, Inc., a leading pet medication and wellness company, today announced that management will participate in the 38 th Annual William Blair Growth Stock Conference in Chicago, ...
LONDON, UK / ACCESSWIRE / May 29, 2018 / If you want access to our free research report on Karyopharm Therapeutics Inc. (NASDAQ: KPTI), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=KPTI as the Company's latest news hit the wire. On May 24, 2018, the Company announced that it has signed an exclusive license agreement with Antengene Corp. for the development and commercialization of four of Karyopharm's novel, oral drug candidates, including selinexor, eltanexor, verdinexor, and KPT-9274. Active-Investors.com is currently working on the research report for PetIQ, Inc. (NASDAQ: PETQ), which also belongs to the Healthcare sector as the Company Karyopharm Therapeutics.
The Eagle, Idaho-based company said it had a loss of 14 cents per share. Earnings, adjusted for non-recurring costs and stock option expense, were 9 cents per share. The results beat Wall Street expectations. ...
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Advanced Micro Devices, Inc. (NASDAQ: AMD ) stock ...
Gainers RF Industries Ltd. (NASDAQ: RFIL ) shares are up 31 percent following a first quarter sales beat. Earnings came in at 5 cents per share in the quarter up from a loss of 2 cents in the same quarter ...
On a per-share basis, the Eagle, Idaho-based company said it had a loss of 25 cents. Earnings, adjusted for pretax expenses and costs related to mergers and acquisitions, were 21 cents per share. The results ...